Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-04-11

Clinical Trial Update: Alprostadil in Maculopathy Study (AIMS) [Phase 3]

View source ↗

Summary

Phase 3 trial of alprostadil for macular degeneration was terminated; results were posted on 2011-04-11.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALPROSTADIL (ALPROSTADIL)

Snippet

Sponsor: UCB Pharma | Conditions: Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2011-04-11